A Phase 3 interventional study of Valsartan/amlodipine 160/5 mg and Valsartan 160 mg in Essential Hypertension, sponsored by Novartis. Completed at 2 sites. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-05-24.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Essential Hypertension by Novartis — none open to participants now, none under way, none of them phase 3. Essential Hypertension · Novartis.
Among the 27 studies in Essential Hypertension by Novartis, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2009, is one of 15 in phase 3, and was the 11th registered.
480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.
Browse Essential Hypertension studies →None of the 27 studies in Essential Hypertension by Novartis is open now. The open studies under Essential Hypertension, anywhere →
Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 16 · Phase 4 5
First in 2005; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 932 is above the median of 144 across 406 interventional studies indexed under Essential Hypertension.
Median enrollment 506 across the 25 interventional studies, 20,984 across the 2 observational. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Essential Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and \<110 mmHg) on valsartan 160 mg alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed as having essential diastolic hypertension, as follows:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
Drug: Valsartan 160 mg · Drug: Placebo
One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks
Drug: Valsartan/amlodipine 160/5 mg · Drug: Placebo
Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.
Drug: Valsartan 160 mg
Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
Also known as: Exforge® 160/5mg
Valsartan 160 mg capsule taken orally once daily.
Also known as: Diovan® 160mg
1 capsule or tablet taken orally once daily
Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint
Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSDBP as a covariate.
Time frame: Baseline and Week 8
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint
Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSSBP as a covariate
Time frame: Baseline and Week 8
Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint
The percentage of participants with a Diastolic Blood Pressure Response defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \< 90 mmHg or a \>= 10 mmHg reduction from baseline.
Time frame: Baseline and Week 8
Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint
The percentage of participants with Diastolic Blood Pressure Control defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \< 90 mmHg.
Time frame: Week 8
Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint
The percentage of participants with Overall Blood Pressure Control defined as the percentage of participants with a Mean Sitting Systolic Blood Pressure (MSSBP)/Mean Sitting Diastolic Blood Pressure (MSDBP) \< 140/90 mmHg.
Time frame: Week 8
932 participants were entered into the single-blind valsartan 160 mg arm. 278 participants were discontinued from the single-blind arm. 654 participants were randomized into the double-blind treatment phase; 329 to the Valsartan/amlodipine arm and 325 to the valsartan alone arm.
| Milestone | Single-Blind Run -In Valsartan 160 mg | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg |
|---|---|---|---|
| Started | 932 | 0 | 0 |
| Completed | 654 | 0 | 0 |
| Not completed | 278 | 0 | 0 |
| Withdrew: Withdrawal by subject | 32 | 0 | 0 |
| Withdrew: Adverse event | 11 | 0 | 0 |
| Withdrew: Abnormal test procedure result(s) | 96 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 7 | 0 | 0 |
| Withdrew: Abnormal laboratory value | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 0 |
| Withdrew: Administrative problems | 82 | 0 | 0 |
| Withdrew: Condition no longer requires study drug | 45 | 0 | 0 |
| Milestone | Single-Blind Run -In Valsartan 160 mg | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg |
|---|---|---|---|
| Started | 0 | 329 | 325 |
| Full analysis set (fas) | 0 | 328 | 323 |
| Completed | 0 | 319 | 306 |
| Not completed | 0 | 10 | 19 |
| Withdrew: Adverse event | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 8 | 13 |
| Withdrew: Abnormal test procedure result(s) | 0 | 0 | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSDBP as a covariate.
| mmHg | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg |
|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint | -10.3 ± 0.39 | -6.6 ± 0.40 |
Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSSBP as a covariate
| mmHg | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg |
|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint | -14.9 ± 0.61 | -7.0 ± 0.61 |
The percentage of participants with a Diastolic Blood Pressure Response defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \< 90 mmHg or a \>= 10 mmHg reduction from baseline.
| Percentage of Participants | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg |
|---|---|---|
| Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint | 70.1 | 52.6 |
The percentage of participants with Diastolic Blood Pressure Control defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \< 90 mmHg.
| Percentage of Participants | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg |
|---|---|---|
| Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint | 65.9 | 50.8 |
The percentage of participants with Overall Blood Pressure Control defined as the percentage of participants with a Mean Sitting Systolic Blood Pressure (MSSBP)/Mean Sitting Diastolic Blood Pressure (MSDBP) \< 140/90 mmHg.
| Percentage of Participants | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg |
|---|---|---|
| Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint | 61.3 | 39.3 |
Collected over Week 8. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Valsartan/Amlodipine 160/5 mg | — | 0/329 (0%) | 0/329 (0%) |
| Valsartan 160 mg | — | 1/325 (0.3%) | 0/325 (0%) |
| Event | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg |
|---|---|---|
| Uterine polypReproductive system and breast disorders | 0/329 | 1/325 |
| Age Continuous(years) | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg | Total |
|---|---|---|---|
| Mean | 52.9 ± 9.47 | 53.1 ± 9.41 | 53.0 ± 9.43 |
| Sex: Female, Male(Participants) | Valsartan/Amlodipine 160/5 mg | Valsartan 160 mg | Total |
|---|---|---|---|
| Female | 141 | 150 | 291 |
| Male | 187 | 173 | 360 |
The record gives a start of Sep 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.